Long‐acting beta2‐agonists vs placebo
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
- Long‐acting beta₂‐agonists for chronic obstructive pulmonary disease 2013 · Cochrane Headline outcomes onlyOR 0.9 [0.75, 1.08]23 studies · 14079 participantsModerate